Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Facilitated PCI in patients with ST-elevation myocardial infarction.
Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, Andersen HR, Betriu A, Savonitto S, Adamus J, Peruga JZ, Kosmider M, Katz O, Neunteufl T, Jorgova J, Dorobantu M, Grinfeld L, Armstrong P, Brodie BR, Herrmann HC, Montalescot G, Neumann FJ, Effron MB, Barnathan ES, Topol EJ; FINESSE Investigators. Ellis SG, et al. Among authors: herrmann hc. N Engl J Med. 2008 May 22;358(21):2205-17. doi: 10.1056/NEJMoa0706816. N Engl J Med. 2008. PMID: 18499565 Free article. Clinical Trial.
Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial.
Herrmann HC, Moliterno DJ, Ohman EM, Stebbins AL, Bode C, Betriu A, Forycki F, Miklin JS, Bachinsky WB, Lincoff AM, Califf RM, Topol EJ. Herrmann HC, et al. J Am Coll Cardiol. 2000 Nov 1;36(5):1489-96. doi: 10.1016/s0735-1097(00)00923-2. J Am Coll Cardiol. 2000. PMID: 11079647 Free article. Clinical Trial.
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L; TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Topol EJ, et al. Among authors: herrmann hc. N Engl J Med. 2001 Jun 21;344(25):1888-94. doi: 10.1056/NEJM200106213442502. N Engl J Med. 2001. PMID: 11419425 Free article. Clinical Trial.
Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
Stone GW, Moliterno DJ, Bertrand M, Neumann FJ, Herrmann HC, Powers ER, Grines CL, Moses JW, Cohen DJ, Cohen EA, Cohen M, Wolski K, DiBattiste PM, Topol EJ. Stone GW, et al. Among authors: herrmann hc. Circulation. 2002 May 21;105(20):2347-54. doi: 10.1161/01.cir.0000017635.82128.8c. Circulation. 2002. PMID: 12021219 Clinical Trial.
Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up.
Roffi M, Moliterno DJ, Meier B, Powers ER, Grines CL, DiBattiste PM, Herrmann HC, Bertrand M, Harris KE, Demopoulos LA, Topol EJ; TARGET Investigators. Roffi M, et al. Among authors: herrmann hc. Circulation. 2002 Jun 11;105(23):2730-6. doi: 10.1161/01.cir.0000018123.02672.c7. Circulation. 2002. PMID: 12057986 Clinical Trial.
Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.
Moliterno DJ, Yakubov SJ, DiBattiste PM, Herrmann HC, Stone GW, Macaya C, Neumann FJ, Ardissino D, Bassand JP, Borzi L, Yeung AC, Harris KA, Demopoulos LA, Topol EJ; TARGET investigators. Moliterno DJ, et al. Among authors: herrmann hc. Lancet. 2002 Aug 3;360(9330):355-60. doi: 10.1016/S0140-6736(02)09605-8. Lancet. 2002. PMID: 12241774 Clinical Trial.
Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial.
Ross MJ, Herrmann HC, Moliterno DJ, Blankenship JC, Demopoulos L, DiBattiste PM, Ellis SG, Ghazzal Z, Martin JL, White J, Topol EJ. Ross MJ, et al. Among authors: herrmann hc. J Am Coll Cardiol. 2003 Sep 17;42(6):981-8. doi: 10.1016/s0735-1097(03)00913-6. J Am Coll Cardiol. 2003. PMID: 13678916 Free article. Clinical Trial.
Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
Ellis SG, Armstrong P, Betriu A, Brodie B, Herrmann H, Montalescot G, Neumann FJ, Smith JJ, Topol E; Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events Investigators. Ellis SG, et al. Am Heart J. 2004 Apr;147(4):E16. doi: 10.1016/j.ahj.2003.07.025. Am Heart J. 2004. PMID: 15077099 Clinical Trial.
362 results